Most of the criticism of the Cass Review comes from the US. Most of Europe has either stopped prescribing puberty blockers and cross sex hormones for minors or never did in the first place. The UK is joining the consensus among the majority of developed countries regarding treatment of gender dysphoric youth, now the US and Canada stand as the sole outliers.